177Lu-DOTATATE in Combination with PARP Inhibitor Olaparib Is Feasible in Patients with Somatostatin-Positive Tumors: Results from the LuPARP Phase I Trial.
Saved in:
| Title: | 177Lu-DOTATATE in Combination with PARP Inhibitor Olaparib Is Feasible in Patients with Somatostatin-Positive Tumors: Results from the LuPARP Phase I Trial. |
|---|---|
| Authors: | Hallqvist, Andreas1,2 (AUTHOR) andreas.hallqvist@vgregion.se, Brynjarsdóttir, Elva1,2 (AUTHOR), Krantz, Tomas1 (AUTHOR), Sjögren, Marie1 (AUTHOR), Svensson, Johanna1,2 (AUTHOR), Bernhardt, Peter3,4 (AUTHOR) |
| Source: | Journal of Nuclear Medicine. May2025, Vol. 66 Issue 5, p707-712. 6p. |
| Database: | Engineering Source |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 01615505 |
|---|---|
| DOI: | 10.2967/jnumed.124.268902 |
